HXBM
vs
S&P 500
HXBM
S&P 500
Over the past 12 months, HXBM has underperformed S&P 500, delivering a return of -86% compared to the S&P 500's +37% growth.
Stocks Performance
HXBM vs S&P 500
Performance Gap
HXBM vs S&P 500
Performance By Year
HXBM vs S&P 500
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Helix BioMedix Inc
Glance View
Helix BioMedix, Inc. is a biopharmaceutical company, which focuses on drug development for treatment of rare dermatological diseases, such as Xeroderma Pigmentosum. The company is headquartered in Bothell, Washington and currently employs 8 full-time employees. The company went IPO on 2000-07-25. The firm is focused on drug development for treatment of rare dermatological diseases. The firm's research and development (R&D) consists of a proprietary library of patented bioactive peptides based on the body’s innate immunity. The firm is focused on developing HB4208 for treatment of the rare disease Xeroderma Pigmentosum (XP). HB4208 is a polypeptide DNA Damage Response (DDR) enzyme that is based on cellular repair pathways. HB4208 is in the preclinical development Phase. The firm is also engaged in identifying the precise peptides needed to stimulate cellular processes and control cell wall defense. Using the specific amino acid sequence for the desired activity, the Company's peptides work with targeted precision to provide optimal skin enhancing results in cosmeceutical and over the counter (OTC) formulations. Its peptides include Oligopeptide-10, Palmitoyl Hexapeptide-14 and others.
